What a GLP-1 maintenance dose means, on the label and in practice

"Maintenance dose" is one of the most searched GLP-1 terms, and it causes real confusion. On a product label, it means a specific dose the label tells prescribers to settle on after titration. In conversation with a provider, people often use it to mean the dose they stay on to hold onto progress. This article separates the two, using the FDA-approved labels and the main clinical trials.

It is educational content, not medical advice. Any dose decision belongs to a licensed provider.

What "maintenance dose" means on a GLP-1 label

GLP-1 medications start at a low dose and increase in steps to reduce side effects. Once titration ends, the label names one or more maintenance doses: the dose or doses studied for ongoing use.

A labeled maintenance dose is not necessarily the highest dose. It is also not a statement about how long someone stays on treatment. Those are separate questions.

Semaglutide maintenance dose

For Wegovy injection, the maintenance phase begins at week 17. For weight reduction in adults, the maintenance dose is either 2.4 mg once weekly (recommended) or 1.7 mg once weekly [1]. The label tells prescribers to consider treatment response and tolerability when choosing [1].

Since March 2026, the label also allows a further increase to a maximum of 7.2 mg weekly. That option is for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated [1]. Wegovy tablets have a single maintenance dose of 25 mg once daily, reached from day 91 [1].

The two labeled injection maintenance doses have trial data. In one 68-week trial in East Asian adults, average weight change was -9.6% on 1.7 mg, -13.2% on 2.4 mg, and -2.1% on placebo [1]. These results describe the FDA-approved branded product in that trial population.

Ozempic maintenance dose

Ozempic is approved for adults with type 2 diabetes, not for weight management. After a four-week start at 0.25 mg, its label uses 0.5 mg weekly as the first maintenance dose [2]. If more blood sugar control is needed, the label allows increases to 1 mg and then 2 mg, each after at least four weeks [2].

So for Ozempic, the maintenance dose can be 0.5 mg, 1 mg, or 2 mg, depending on glycemic response [2].

Tirzepatide maintenance doses

For Zepbound, the label starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg steps at least four weeks apart [3]. The labeled maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg once weekly, with 15 mg the maximum [3].

What research shows about continuing versus stopping

Several randomized trials tested what happens when people who have lost weight on a GLP-1 medication either continue it or switch to placebo. All studied FDA-approved branded products, and their results do not describe compounded formulations.

• STEP 4 (semaglutide 2.4 mg). After a 20-week run-in on semaglutide, participants were randomized. From week 20 to week 68, those who continued had an average further weight change of -7.9%, while those switched to placebo regained an average of 6.9% [1, 4].
• SURMOUNT-4 (tirzepatide). After 36 weeks on the maximum tolerated dose, those who continued had an average further change of -5.5% through week 88, while those switched to placebo regained an average of 14% [5].
• STEP 1 extension. One year after semaglutide 2.4 mg was stopped, participants had regained about two-thirds of their prior weight loss on average [6].

These are averages, and results vary by person. The trials show that stopping is often followed by regain. They do not tell any individual how long to continue or at what dose.

Lower-dose maintenance at provider discretion

Some providers prescribe GLP-1 medications at doses below the labeled maintenance range, an approach often called microdosing. This is a prescribing choice made at the provider's discretion for a specific patient. It is not a labeled dosing schedule.

Research on maintenance with doses below the labeled range is limited. There is not enough published evidence to say that lower doses cause fewer side effects or produce better long-term weight maintenance than labeled doses. Our articles on what microdosing GLP-1 medications means and our complete guide to microdosing semaglutide explain how the approach is described.

Compounded semaglutide and tirzepatide products are not FDA-approved and do not undergo FDA review for safety, effectiveness, or quality before they are marketed [7]. FDA recommends that compounded drugs be used only when a patient's medical needs cannot be met by an available FDA-approved drug. Federal and state laws also restrict when commercially available medications may be compounded. A compounded product should not be considered a generic or FDA-approved equivalent of Wegovy, Ozempic, or Zepbound. Whether compounding is clinically appropriate and legally permissible depends on the individual patient and applicable compounding requirements. Data from clinical trials of Wegovy and Zepbound, including STEP 4 and SURMOUNT-4, should not be assumed to establish the safety, effectiveness, quality, potency, or bioequivalence of a compounded product.

How a provider may decide

Choosing a maintenance dose is an individual decision. A licensed provider typically weighs:

• How you have responded at each dose so far.
• Side effects and how well you tolerate them.
• Your health history, including conditions and other medications such as insulin or a sulfonylurea [1].
• Your goals, including whether the focus has shifted from loss to long-term management.

Like any prescription medication, GLP-1 medications carry risks and possible side effects, including a boxed warning about thyroid C-cell tumors seen in rodents [1, 2, 3]. Your provider reviews these with you. These are not comprehensive lists of risks or contraindications; patients should review the prescribing information and discuss their medical history with their clinician. For habits that support the long term, see microdosing GLP-1 for long-term weight management.

Common questions

Do you stay on the maintenance dose forever?

Not necessarily. In STEP 4 and SURMOUNT-4, people switched to placebo regained weight on average [4, 5], but neither trial set a lifelong rule. How long to continue, and at what dose, is a decision you make with your provider.

Is a lower maintenance dose as effective?

Among labeled doses, the Wegovy label reports smaller average weight loss on 1.7 mg than on 2.4 mg in one trial [1]. For doses below the labeled range, research is limited, and no effectiveness comparison can be made.

Is the maintenance dose the highest dose?

Not always. For Wegovy, the labeled maintenance dose is 1.7 mg or 2.4 mg, while the highest labeled dose is now 7.2 mg for selected adults [1]. Our week-by-week semaglutide dosing chart shows how the steps fit together.

Can I switch to a lower dose myself?

Do not change your dose on your own. A licensed clinician should determine any dose change based on your current dose, tolerability, response, and other clinical factors. Changing on your own can affect side effects and how you respond.

Next steps

If you are thinking about what the long term looks like on a GLP-1 medication, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review. Any medication preference you indicate is only a starting point for discussion. A licensed clinician independently determines whether prescription treatment is medically appropriate and, if so, which medication, dose, and treatment plan are appropriate based on your clinical evaluation.

Explore Luvo's Microdosing Program.